Loading clinical trials...

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine | Clinical Trials | Clareo Health

RECRUITINGPHASE4

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

NCT05850091•Massachusetts General Hospital

View on ClinicalTrials.gov

Summary

The goal of this double-blind randomized controlled trial is to determine how treatment with high intensity statin, low-dose colchicine, and their combination modulates progression and composition of coronary atherosclerosis in individuals with high polygenic risk for coronary artery disease.

Detailed Description

The main question PROACT 2 aims to answer is whether and how single or dual targeting of cholesterol-lowering and inflammation modulates coronary plaque in individuals with high polygenic risk and subclinical coronary atherosclerosis. This is a double-blind randomized controlled trial of 200 individuals with high polygenic risk for coronary artery disease and subclinical plaque on coronary computed tomography angiography. Participants will be randomized into four equal treatment groups: group A receiving a placebo daily, group B receiving rosuvastatin 20mg daily, group C receiving colchicine 0.6mg daily, and group D receiving both rosuvastatin 20mg daily and colchicine 0.6mg daily. The primary outcome is change in total non-calcified plaque volume on coronary computed tomography angiography from baseline to one year. Multiple secondary plaque imaging and biomarker outcomes will be explored in this pilot mechanistic trial.

Eligibility

Age

40 - 75 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Males and females between 40 and 75 years of age capable and willing to provide informed consent
•Participant has high CAD PRS as defined on a clinical test
•Participant with subclinical atherosclerosis defined as plaque visible on CCTA and causing \<70% luminal stenosis

Exclusion Criteria

•Participant with a history of cardiovascular disease, defined by a diagnosis of coronary artery disease, peripheral artery disease, or cerebrovascular disease
•Participant with a history of Liver disease (cirrhosis, active hepatitis, or severe hepatic disease) or any of the following recent lab results and determined to be non-transient: alanine aminotransferase greater than 3 times the upper limit of normal or total bilirubin greater than 2 times the upper limit of normal (unless due to Gilbert syndrome)
•Participant with estimated glomerular filtration rate \<60 mL/min/1.73 m2 or creatinine greater than 2 times the upper limit of normal
•Patient with history of an allergic reaction or significant sensitivity to iodinated contrast, colchicine, or statins
•Patient currently taking LDL cholesterol lowering or anti- inflammatory medications including colchicine
•Participants requiring regular drugs known to be potent CY2P inhibitors (eg. ketoconazole, clarithromycin)
•Female patient who is pregnant, or breast-feeding or is considering becoming pregnant during the study
•Participant with BMI ≥ 40 kg/m2
•Participant unable to provide informed consent
•Participant unable to hold breath for 10 seconds

Locations (1)

Massachusetts General Hospital

Boston, Massachusetts, United States

Key Dates

Start Date

December 7, 2023

Primary Completion Date

February 1, 2026

Completion Date

February 1, 2027

Last Updated

July 30, 2025

Enrollment

200

ESTIMATED participants

Conditions

Coronary Artery Disease

Interventions

Rosuvastatin

DRUG

Colchicine

DRUG

Placebo

DRUG

Contacts

Roukoz Abou-Karam, MD

CONTACT

(617)-643-4842 proact@mgb.org

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: July 30, 2025Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Polygenic Risk-based Detection of Subclinical Coronary Atherosclerosis and Intervention With Statin and Colchicine

Inclusion Criteria

Exclusion Criteria

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

"Erectile Function After PCI in MI and Non-MI Patients"

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

Product Surveillance Registry

Essential Pro Study ( rEPIC04E-HK )

Factors Affect Outcomes in Cardiovascular Surgery